Gallium-67 Scanning in Sjögren's Syndrome: Concise Communication

R. Deaver Collins, Jr., Gene V. Ball, and Joseph R. Logic

University of Alabama-Birmingham, Birmingham, Alabama

We performed gallium-67 scans in 12 patients with primary or secondary Sjögren's syndrome (SS). Salivary-gland uptake of gallium-67 was noted in four of five patients with primary SS. Pulmonary uptake was observed in ten of 12 patients. Chest radiographs were essentially normal in all patients, although 60% complained of significant dyspnea with exertion. The gallium-67 scan may prove to be a sensitive noninvasive diagnostic test for lung and mediastinal involvement by either primary or secondary SS, and for salivary-gland involvement in primary SS.

J Nucl Med 25: 299-302, 1984

Sjögren's syndrome (SS) is defined by clinical and laboratory parameters, but a sensitive noninvasive anatomic test for salivary-gland inflammation is still lacking. The pertechnetate scan correlates roughly with salivary-gland biopsy findings, but is a direct test of secretory function rather than of glandular infiltration (1). Sialography, while demonstrating ductal and acinar anatomy (2), detects destructive changes occurring relatively late in the inflammatory process. Neither test is entirely specific nor sensitive for the diagnosis of SS (3,4). The minor salivary-gland biopsy-which is currently the most accurate test for the lymphocytic salivary-gland inflammation of SS (3)—is invasive and ill-suited for use as a follow-up procedure. There have been scattered reports of gallium-67 uptake in the lacrimal and salivary glands of patients with SS (5,6), as might be expected from the known affinity of gallium for lymphocytes in vitro (7) and for lymphomas in vivo (8). As part of a prospective study of SS, we therefore performed gallium scans as well as minor salivary-gland biopsies to determine whether a correlation might exist in this group of patients.

MATERIALS AND METHODS

Patient sample. Patients from the clinic population with suspected or known SS were offered the opportunity to participate in the study. SS was defined as previously described (3) by two of these three criteria: xerostomia, xerophthalmia, and another well-defined connectivetissue disease. We studied five patients with primary SS (sicca syndrome alone) and seven with secondary SS: five of seven with classical or definite rheumatoid arthritis (RA), and two of seven with systemic lupus erythematosus (SLE) as defined by ARA criteria (9,10)). Informed consent was obtained and the patients were hospitalized in the General Clinical Research Center. Salivary-gland biopsies were graded as described by Tarpley et al. (11).

Scintigraphy. Each patient received 4-5 mCi of gallium-67 citrate, and 48 hr later was imaged on either a single- or dual-probe rectilinear scanner or a multicrystal scanning device, using an 85-325 keV window and appropriate collimation. Anterior and posterior full-body images were obtained. The pulmonary uptake of gallium was graded as follows (12): 0 = normal, 1+ = bone > lung, 2+ = lung-bone, 3+ = liver > lung > bone, 4+ = lung ≥ liver.

RESULTS

Selected clinical and laboratory results are listed in Table 1. Two of ten patients were receiving corticosteroids and three of ten received gold salts (2) or hydroxychloroquine (1) for RA at time of study. Seven of ten patients had anti-SSA (Ro) antibody (four of seven with primary SS) and four of ten had anti-SSB (La) antibody (4/4 with primary SS). Precipitating antibodies to SSA

Received July 21, 1983; revision accepted Sept. 30, 1983.

For reprints contact: Gene V. Ball, MD, 602 MEB, 1813 6th Ave. So., University Station, Birmingham, AL 35294.

Patient Age Se 1 - 54 - 75 5 - 51 - 7 6 - 61 - 7 46	Sex Diagnosis							Gallium uptake ¹	take ¹	
		D.O.D.†	SSA*	SSB•	Biopsy [‡]	CXR⁵	S	-	•	Σ
	M RA, 2°SS	11	+	1	Ξ	z	I	I	2+	+
	M RA, 2°SS	ŝ	I	ł	Ξ	z	I	ł	ŧ	+
_	F RA, 2°SS	ŝ	ł	I	≡	z	I	I	ŧ	I
	F RA, 2°SS	ŝ	ł	I	_	Blunt CPA	I	ł	2+	I
	M RA, 2°SS	₽	I	I	=	z	I	I	2+	+
	F SLE, 2°SS	e	÷	I	=	z	I	I	0	I
	F SLE, 2°SS	-	+	I	_	z	I	I	<u>+</u>	1
61 F	F 1°SS	5	+	+	2	z	+	I	: ±	+
26 F	F 1°SS	-	+	+	Ξ	z	+	+	0	1
10 76 F	F 1°SS	13	ł	ł	2	z	+++(.75)			
							++	I	ŧ	I
61 F	F 1°SS	80	+	+	≥	z	+ + +	ł	2+	I
12 73 F	F 1°SS	15	+	+	≥	z	(22.)+++		3+('77)	
							+('81)			
							I	ł	0	1
 Anti-SSA and SSB antibodies. 	ibodies.									
[†] Duration of disease (SS), yr.	S), yr.									
[‡] Minor salivary gland, class (see text).	lass (see text).									
est radiograph, N =	= cost	chrenic angle.								
ite of study = 1982- salivary (submandib	 Date of study = 1982-83 unless otherwise st S = salivary (submandibular and/or parotid). 	s specified. L = lacrimal, P = pulmonary. M = mediastinal.	pulmonary.	M = mediast	tinal					
ng the time of the st 3: hydroxychloroguin	During the time of the studies, certain patients were being treated with hydroxychloroquine or corticosteroids, namely: Patient 2: aurothioglucose 50 mg i.m. weekly, Patient 3: hydroxychloroquine 200 mg time weekly: prednisone 10 mg daily. Patient 4: prednisone 5 mg daily. Patient 5: aurothioglucose 50 mg i.m. weekly.	were being tre rednisone 10 mo	ted with hyd	Iroxychloroqi t 4: prednisor	uine or corticos re 5 ma daily. P.	steroids, namely: atient 5: aurothioc	ts were being treated with hydroxychloroquine or corticosteroids, namely: Patient 2: aurothioglucose 50 mg i.m. weekly, ts vere being treated with hydroxychloroquine or corticosteroids, namely: Patient 2: aurothioglucose 50 mg i.m. weekly,	ioglucose	50 mg i.m. Patiant 6: pre	weekh
10 mg every other day.)	,	:		0					5

react with antigens obtained from a human lymphoid cell line as well as with the soluble cytoplasmic antigen termed Ro. SSB is a similar lymphoid nuclear antigen thought to be identical to the cytoplasmic antigen termed La. A high but variable percentage of patients with Sjögren's Syndrome have antibodies to SSB. Antibodies to SSA are less common and still less specific. No patient had known pseudolymphoma or malignancy. Note that Patients 10 and 12 both had more intense parotid and pulmonary uptake of gallium in 1977 than in 1983; uptake disappeared from both lungs and parotid glands in Patient 12. No significant changes in Patient 12's clinical status or therapy occurred during this interval, although her serum gamma globulin dropped from 3.27 to 2.31 g/100 ml, and her Westergren ESR fell from 99-105 mm/hr (1975-1981) to 55 mm/hr (1982). Representative scans are shown in Fig. 1.

DISCUSSION

There are no striking differences between primary and secondary SS, in duration of disease or salivary-gland enlargement, by which to explain the absence of glandular gallium uptake in the seven patients with secondary SS, although the number of patients is too small for statistical analysis. Five out of five patients with primary SS have had positive salivary scans at some time (4/5 at)this analysis). As is usually the case, our patients with primary SS tended to have more extensive lymphocytic infiltration on biopsy than did those with secondary SS; nevertheless, Patients 1 and 3 had Grade III biopsies but negative scans, and Patient 12, whose salivary gland is currently the most severely infiltrated of all, has had a reversion of her salivary scan to negative. Furthermore, four patients with secondary SS had significant parotid-gland swelling at the time of negative salivary scans; two of the four patients with primary SS and positive scans also had parotid enlargement at this examination. Differences between primary and secondary SS in sub-




FIG. 1. Patient 10: Whole-body scans at 48 hr after injection of 5 mCi Ga-67. Note left submandibular and parotid uptake (upper arrow), and 1+ pulmonary uptake (lower arrow).

sets of infiltrating leukocytes (which might by inference account for differing affinities for gallium) have not been found consistently (12), and typing was not performed on these biopsies. In this small sample, the sensitivity of the gallium scan in primary SS (\sim 80%) appears to be similar to that of the anti-SSB antibody (60-75%), a sensitive noninvasive laboratory test for primary SS (13). While one is unlikely to confuse sarcoidosis and primary SS, salivary uptake of gallium in the former (14) mandates study of a population in which SS is part of the differential diagnosis before commenting on specificity. In addition, the sensitivity and anatomic accuracy of this procedure might be improved further by detailed imaging of the head region with lateral and oblique views, as has been described for pertechnetate (Tc-99m) scans (15).

The high incidence of pulmonary parenchymal uptake of gallium, not only in secondary (six of seven) but in primary SS (four of five), is intriguing and not previously reported. Three of our ten patients complained of chronic bronchitis, and six of the ten had one-block dyspnea on exertion. Only two patients smoked or had coronary heart disease (Killip Class I). Our data suggest that subclinical lung disease may be much more common in primary SS than the 10% that is recognized clinically (16). Although all of the chest radiographs were interpreted as normal, 10% of patients with abnormal pulmonary function tests and biopsy-proven interstitial lung disease may have normal chest radiographs (17). Furthermore, previous reports have documented the sensitivity of gallium for subclinical pulmonary disease (18). More extensive longitudinal investigation of lung function and anatomy will be required to establish the significance both of the pulmonary parenchymal and the mediastinal uptake of gallium-67 noted in our patients.

ACKNOWLEDGMENT

Supported in part by a training grant from the Alabama Chapter of the Arthritis Foundation and NIH Grant RR032.

REFERENCES

- 1. ALARCON-SEGOVIA D, IBANEZ G, HERNANDEZ-ORTIZ, J, et al: Salivary gland involvement in diseases associated with Sjögren's syndrome: Radionuclide and roentgenographic studies. J Rheumatol 1:159-165, 1974
- DIJKSTRA PF. Classification and differential diagnosis of sialographic characteristics in Sjögren's syndrome. Semin Arthritis Rheum 10:10-17, 1980
- 3. KASSAN SS, GARDY M: Sjögren's syndrome: An update and overview. Am J Med 64:1037-1046, 1978
- 4. SCHALL GL, ANDERSON LG, WOLF RO, et al: Xerostomia in Sjögren's syndrome: Evaluation by sequential salivary scintigraphy. JAMA 216:2109-2116, 1971
- LOGIC JR, BALL GV, TAUXE WN: Uptake of 67-gallium in parotid glands of patients with Sjögren's syndrome. J Nucl Med 17:530, 1976 (abst)
- 6. WEINREB RN, YAVITZ EQ, O'CONNOR GR, BARTH RA.

Lacrimal gland uptake of gallium citrate Ga-67. Am J Ophthalmol 92:16-20, 1981

- MERZ T, MALMUD L, MCKUSICK K, et al: The mechanism of ⁶⁷Ga association with lymphocytes. *Cancer Res* 34: 2495–2499, 1974
- MCCAFFREY JA, RUDDERS RA, KAHN PC, et al: Clinical usefulness of ⁶⁷gallium scanning in the malignant lymphomas. *Am J Med* 60:523-530, 1976
- 9. A committee of the american rheumatism association: 1958 Revision of diagnostic criteria for rheumatoid arthritis. Arthritis Rheum 2:16-20, 1959
- TAN EM, COHEN AS, FRIES JF, et al: Special article: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 11:1271-1277, 1982
- TARPLEY TM, ANDERSON LG, WHITE CL: Minor salivary gland involvement in Sjögren's syndrome. J Oral Surg 37: 64-74, 1974
- 12. TALAL N, SYLVESTER RA, DANIELS TE, et al: T and B

lymphocytes in peripheral blood and tissue lesions in Sjögren's syndrome. J Clin Invest 53:180-189, 1974

- 13. MOUTSOPOULOS HM, CHUSED TM, MANN DL, et al: Sjögren's Syndrome (sicca syndrome): Current issues. Ann Intern Med 92:212-226, 1980
- 14. WIENER SN, PATEL BP: ⁶⁷Ga-citrate uptake by the parotid glands in sarcoidosis. *Radiology* 130:753-755, 1979
- 15. DANIELS TE, POWELL MR, SYLVESTER RA, et al: An evaluation of salivary scintigraphy in Sjögren's syndrome. Arthritis Rheum 22:809-814, 1979
- 16. STRIMLAN CV, ROSENOW EC III, DIVERTIE MB, et al: Pulmonary manifestations of Sjögren's syndrome. Chest 70:354-361, 1976
- 17. EPLER GR, MCLOUD TC, GAENSLER EA: Normal chest roentgenograms in chronic diffuse infiltrative lung disease. N Engl J Med 298:934-939, 1978
- 18. STAAB EV, MCCARTNEY WH: Role of gallium 67 in inflammatory disease. Semin Nucl Med 8:219-234, 1978

Society of Nuclear Medicine 9th Annual Western Regional Meeting October 11-14, 1984 **Doubletree Inn** Monterey, California Announcement and Call for Abstracts The Scientific Program Committee welcomes the submission of abstracts of original contributions in nuclear medicine from members and nonmembers of the Society of Nuclear Medicine for the 9th Annual Western Regional Meeting. Physicians scientists, and technologists-members and nonmembers-are invited to participate. The program will be structured to permit the presentations of papers from all areas of interest in the specialty of nuclear medicine. Abstracts submitted by technologists are encouraged and will be presented at the Scientific Program. Abstracts for the Scientific Program will be published as a Journal Supplement and will be available to all registrants at the meeting. The Western Regional Scholarship and Award Fund will make one award in the name of Norman D. Poe for the most outstanding paper in the field of pulmonary or cardiac nuclear medicine and a second award for an outstanding Technologist paper. The abstracts will be printed from camera-ready copy provided by the authors. Therefore, only abstracts prepared on the official abstract form will be considered. These abstract forms will be available from the Western Regional Chapter office (listed below) after April 2, 1984. Abstract forms will be sent to members of the Pacific Northwest, Northern California, Southern California, and Hawaii Chapters in a regular mailing in early May, 1984. All other requests will be sent on an individual basis. All participants will be required to register and pay the appropriate fee. Please send the original abstract form, supporting data, and seven copies to: Justine J. Parker, Administrator 9th Western Regional Meeting, SNM P.O. Box 40279 San Francisco, CA 94140 For information contact Becci Lynch at the Western Regional SNM office (address above). Tel: (415)647-0722 or 647-1668. The 9th Annual Western Regional Meeting will have commercial exhibits and all interested companies are invited. Deadline for abstract submission: Postmark by midnight, June 22, 1984.